Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma.
Wang Q, Xu C, Wang W, Zhang Y, Li Z, Song Z, Wang J, Yu J, Liu J, Zhang S, Cai X, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Li J, Liu B, Yuan J, Jiang Z, Lin G, Chen X, Pu X, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Guo H, Chu Q, Meng R, Liu X, Wu J, Hu X, Zhou J, Zhu Z, Chen X, Pan W, Pang F, Zhang W, Jian Q, Wang K, Wang L, Zhu Y, Yang G, Lin X, Cai J, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Wang X, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Hao Y, Wang Z, Wan B, Lv D, Yu J, Kang J, Zhang J, Zhang C, Wu L, Shi L, Ye L, Wang G, Wang Y, Gao F, Huang J, Wang G, Wei J, Huang L, Li B, Zhang Z, Li Z, Liu Y, Li Y, Liu Z, Yang N, Wu L, Wang Q, Huang W, Hong Z, Wang G, Qu F, Fang M, Fang Y, Zhu X, Du K, Ji J, Shen Y, Chen J, Zhang Y, Ma S, Lu Y, Song Y, Liu A, Zhong W, Fang W.
Thorac Cancer. 2023 Sep;14(26):2715-2731. doi: 10.1111/1759-7714.15022. Epub 2023 Jul 17.
Engineered lactococcus lactis intrapleural therapy promotes regression of malignant pleural effusion by enhancing antitumor immunity.
Fan Y, Chen A, Zhu J, Liu R, Mei Y, Li L, Sha X, Wang X, Ren W, Wang L, Liu B.
Cancer Lett. 2024 Apr 28;588:216777. doi: 10.1016/j.canlet.2024.216777. Epub 2024 Mar 2.
Updated perspectives on visceral pleural invasion in non-small cell lung cancer: A propensity score-matched analysis of the SEER database.
Liu J, Wang Y, Zhou X, Reng M, Xiang Z, Chang R, Hao W, Sun X, Yang Y.
Curr Probl Cancer. 2025 Jun;56:101205. doi: 10.1016/j.currproblcancer.2025.101205. Epub 2025 Apr 18.
Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion.
Cheng Q, Zuo X, Wang Z, Lu W, Jiang Y, Liu J, Li X, Xu Q, Zhu S, Liu X, Song Y, Zhan P, Lv T.
Respir Res. 2025 May 10;26(1):180. doi: 10.1186/s12931-025-03263-0.
[Unilateral pleural effusion as first manifestation in Takayasu arteritis: a case report and review of literature].
Gui XH, Cao M, Liu Y, Cai HR, Xiao YL.
Zhonghua Jie He He Hu Xi Za Zhi. 2016 Oct 12;39(10):768-772. doi: 10.3760/cma.j.issn.1001-0939.2016.10.006.
Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion.
Li X, Wu G, Chen C, Zhao Y, Zhu S, Song X, Yin J, Lv T, Song Y.
Front Immunol. 2021 Dec 13;12:760683. doi: 10.3389/fimmu.2021.760683. eCollection 2021.
Effects of enhanced recovery after surgery plus pulmonary rehabilitation on complications after video-assisted lung cancer surgery: a multicentre randomised controlled trial.
Zheng Y, Mao M, Li F, Wang L, Zhang X, Zhang X, Wang H, Zhou H, Ji M, Wang Y, Liu L, Zhu Q, Reinhardt JD, Lu X.
Thorax. 2023 Jun;78(6):574-586. doi: 10.1136/thoraxjnl-2021-218183. Epub 2022 Jul 14.
[Analysis of risk factors of multiple fractures of limbs complicated with pleural effusion].
Tan L, Zhang ZT, Qiu XS, Chen YX.
Zhongguo Gu Shang. 2022 Jul 25;35(7):692-7. doi: 10.12200/j.issn.1003-0034.2022.07.019.
Activation and propagation of tumor-infiltrating lymphocytes from malignant pleural effusion and ascites with engineered cells for costimulatory enhancement.
Xu Q, Shao J, Su S, Wei J, Chen F, Meng F, Zhao Y, Du J, Zou Z, Qian X, Liu B.
Cell Immunol. 2018 Sep;331:1-8. doi: 10.1016/j.cellimm.2018.04.006. Epub 2018 Apr 17.
[Idiopathic pleuroparenehymal fibroelastosis: five case reports and review of literature].
Gui XH, Qiu YY, Chen TT, Li H, Dai JH, Cai HR, Xiao YL, Cao M.
Zhonghua Jie He He Hu Xi Za Zhi. 2022 May 12;45(5):453-459. doi: 10.3760/cma.j.cn112147-20210917-00655.
